{"id":"NCT01012323","sponsor":"Octapharma","briefTitle":"A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases","officialTitle":"Clinical Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Patients With Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2009-11-13","resultsPosted":"2017-03-16","lastUpdate":"2017-03-16"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Diseases"],"interventions":[{"type":"BIOLOGICAL","name":"NewGam","otherNames":["Human normal immunoglobulin"]}],"arms":[{"label":"NewGam","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to determine the efficacy of NewGam in preventing serious bacterial infections and to determine the pharmacokinetic profile of NewGam. The safety of NewGam and its effect on quality of life were also evaluated.","primaryOutcome":{"measure":"Number of Serious Bacterial Infections Per Person-year of Treatment","timeFrame":"Baseline to end of the study (up to 12 months)","effectByArm":[{"arm":"NewGam","deltaMin":0.08,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":17},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":51},"commonTop":["Upper respiratory tract infection","Headache","Nasopharyngitis","Sinusitis","Pyrexia"]}}